A Phase III Study of BBI-608 plus nab-Paclitaxel with Gemcitabine in Adult Patients with Metastatic Pancreatic Adenocarcinoma
The purpose of this study is to compare any good and bad effects of using of using BBI-608, in combination with the usual chemotherapy regimen, nab-paclitaxel and gemcitabine in participants with metastatic pancreatic cancer.
Metastatic Pancreatic Cancer
≥ 18 years of age
metastatic pancreatic cancer
18 - 120
Healthy Volunteers Needed
Duration of Participation
If you are randomized to the study drug, you may continue to receive the study drug until your disease worsens or if you have bad side effects.
Knight Cancer Institute Clinical Trials
Boston Biomedical, Inc